Pune-based startup In-Med Prognostics has announced the launch of Oncoshield CT tool for clinical decision support in diagnosing and treating liver and pancreatic cancers. 

In-Med Oncoshield software automatically detects and quantifies lesions in liver and pancreas in CT scans. It automatically calculates volumes and identifies locations of lesions. This significantly enhances diagnostic capabilities and improves patient care especially in preparing for surgery. These insights are produced with over 90% accuracy and very speedily in a matter of minutes.

In-Med’s Oncoshield assists radiologists in the early detection of liver lesions. Early detection is crucial for prompt medical intervention and improved patient outcomes.

The product is currently deployed at the Madras Medical College and the company is offering 30-day free trial to prospective customers and 90-day free trials to its current customers who may be using Neuroshield.

This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy and Neuroshield CT TBI products already operational in over 280 sites in India, Africa, and the Middle East. Neuroshield MRI Volumetry recently received the US FDA 510 clearance for sales in the US market.